Targeting RAS driven tumour immune evasion

Información del proyecto

RASImmune

Identificador del acuerdo de subvención: 834692

DOI

10.3030/834692

Fecha de la firma de la CE 7 Junio 2019

Fecha de inicio 1 Agosto 2019

Fecha de finalización 31 Enero 2026

Financiado con arreglo a

• EXCELLENT SCIENCE - European Research Council (ERC)

Coste total

€ 2 500 000,00

Aportación de la UE

€ 2 500 000,00

Coordinado por

THE FRANCIS CRICK INSTITUTE LIMITED
United Kingdom

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Publicaciones

Peer reviewed articles (12)

An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations

Autores: J. Boumelha, S. de Carné Trécesson, E.K. Law, P. Romero-Clavijo, M.A. Coelho, K. Ng, E. Mugarza, C. Moore, S. Rana, D.R. Caswell, M. Murillo, D.C. Hancock, P.P. Argyris, W.L. Brown, C. Durfee, L.K. Larson, R.I. Vogel, A. Suárez-Bonnet, S.L. Priestnall, P. East, S.J. Ross, G. Kassiotis, M. Molina-Arcas, C. Swanton, R. Harris, J. Downward
Publicado en: Cancer Research, 2022, ISSN 1538-7445
Editor: AACR
DOI: 10.1158/0008-5472.can-22-0325

Combined targeting of G protein‐coupled receptor and EGF receptor signaling overcomes resistance to PI 3K pathway inhibitors in PTEN ‐null triple negative breast cancer

Autores: Davide Zecchin, Christopher Moore, Fanourios Michailidis, Stuart Horswell, Sareena Rana, Michael Howell, Julian Downward
Publicado en: EMBO Molecular Medicine, Edición 12/8, 2020, ISSN 1757-4676
Editor: John Wiley & Sons Ltd.
DOI: 10.15252/emmm.202011987

Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry

Autores: van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, Colliver E, Enfield K, Bah N, Kelly G, Tsang VSK, Mugarza E, Moore C, Hobson P, Levi D, Molina-Arcas M, Swanton C, Downward J
Publicado en: Nature Communications, 2021, ISSN 2041-1723
Editor: Nature Publishing Group
DOI: 10.1038/s41467-021-26214-x

Stratification method based on oncogenic RAS pathway activity predicts outcome in lung adenocarcinoma

Autores: P. East, G.P. Kelly, D. Biswas, M. Marani, D.C. Hancock, C. Swanton, J. Downward, S. de Carné Trécesson
Publicado en: Nature Communications, 2022, ISSN 2041-1723
Editor: Nature Publishing Group
DOI: 10.1038/s41467-022-33290-0

Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets

Autores: Rachel Cooley, Neesha Kara, Ning Sze Hui, Jonathan Tart, Chloë Roustan, Roger George, David C. Hancock, Brock F. Binkowski, Keith V. Wood, Mohamed Ismail, Julian Downward
Publicado en: Wellcome Open Research, Edición 5, 2020, Página(s) 20, ISSN 2398-502X
Editor: Wellcome Trust
DOI: 10.12688/wellcomeopenres.15675.2

Immunotherapy boosts protective antibody responses against endogenous retroviruses in lung adenocarcinoma

Autores: K.W. Ng, J. Boumelha, K.S.S. Enfield, J. Almagro, H. Cha, O. Pich, T. Karasaki, D.A. Moore, R. Salgado, M. Sivakumar, G. Young, M. Molina-Arcas, S. de Carné Trécesson, P. Anastasiou, A. Fendler, L. Au, S.T.C. Shepherd, C. Martínez-Ruiz, C. Puttick, J.R.M. Black, T.B.K. Watkins, H. Kim, S. Shim, N. Faulkner, J. Attig, S. Veeriah, N. Magno, S. Ward, A.M. Frankell, M. Al Bakir, E.L. Lim, M.S. Hill
Publicado en: Nature, 2023, ISSN 1476-4687
Editor: Nature Publishing Group
DOI: 10.1038/s41586-023-05771-9

Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110alpha

Autores: M. Ismail, S.R. Martin, R. George, F. Houghton, G. Kelly, R.A.G. Chaleil, P. Anastasiou, X. Wang, N. O’Reilly, S. Federico, D. Joshi, H. Nagaraj, R. Cooley, N.S. Hui, M. Molina-Arcas, D.C. Hancock, A. Tavassoli, J. Downward
Publicado en: Scientific Reports, 2023, ISSN 2045-2322
Editor: Nature Publishing Group
DOI: 10.1038/s41598-023-28756-0

Micro-CT image acquisition, processing, and segmentation to track lung cancer progression and characterise pulmonary nodules in mice

Autores: M.Z. Thin, C. Moore, T. Snoeks, T. Kalber, J. Downward, A. Behrens
Publicado en: Nature Protocols, 2022, ISSN 1750-2799
Editor: Nature Publishing Group
DOI: 10.1038/s41596-022-00769-5

Lung adenocarcinoma promotion by air pollutants

Autores: W. Hill, E.L. Lim, C.E. Weeden, C. Lee, M. Augustine, K. Chen, F-C. Kuan, F. Marongiu, E.J. Evans Jr, D.A. Moore, F.S. Rodrigues, O. Pich, B. Bakker, H. Cha, R. Myers, F. van Maldegem, J. Boumelha, S. Veeriah, A. Rowan, C. Naceur-Lombardelli, T. Karasaki, M. Sivakumar, S. De, D.R. Caswell, A. Nagano, J.R.M. Black, C. Martínez-Ruiz, M.H. Ryu, R.D. Huff, S. Li, M-J. Favé, A. Magness, A. Suárez-Bo
Publicado en: Nature, 2023, ISSN 1476-4687
Editor: Nature Publishing Group
DOI: 10.1038/s41586-023-05874-3

Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers

Autores: E. Mugarza, F. van Maldegem, J. Boumelha, C. Moore, S. Rana, M. Llorian Sopena, P. East, R. Ambler, P. Anastasiou, P. Romero Clavijo, K. Valand, M. Cole, M. Molina-Arcas, J. Downward
Publicado en: Science Advances, 2022, ISSN 2375-2548
Editor: AAAS
DOI: 10.1126/sciadv.abm8780

Palmitoyl transferase ZDHHC20 promotes pancreatic cancer metastasis

Autores: G. Tomić, C. Sheridan, A. Refermat, M. Baggelaar, J. Sipthorp, B. Sudarshan, C.A. Ocasio, A. Suarez-Bonnet, S. Priestnall, E. Herbert, E. Tate, J. Downward
Publicado en: Cell Reports, 2024, ISSN 2211-1247
Editor: Cell Press
DOI: 10.1016/j.celrep.2024.114224

In vivo CRISPR screen identifies KRAS-induced COX-2 as a driver of immune evasion and immunotherapy resistance in lung cancer

Autores: J. Boumelha, A. de Castro, N. Bah, H. Cha, S. de Carné Trécesson, S. Rana, P. Anastasiou, E. Mugarza, C. Moore, R. Goldstone, P. East, K. Litchfield, S-H. Lee, M. Molina-Arcas, J. Downward
Publicado en: Cancer Research, 2024, ISSN 1538-7445
Editor: AACR
DOI: 10.1158/0008-5472.can-23-2627

Other (2)

Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot

Autores: Panayiotis Anastasiou, Chris Moore, Sareena Rana, Andrea de Castro, Mona Tomaschko, Jesse Boumelha, Edurne Mugarza, Cristina Blaj, Sophie de Carné, Robert Goldstone, Jacqueline A.M. Smith, Elsa Quintana, Miriam Molina-Arcas, Julian Downward
Publicado en: 2024
Editor: Cold Spring Harbor Press
DOI: 10.1101/2024.01.15.575765

Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses

Autores: Megan Cole, Panayiotis Anastasiou, Claudia Lee, Chris Moore, Edurne Mugarza, Martin Jones, Karishma Valand, Sareena Rana, Emma Colliver, Mihaela Angelova, Katey S.S. Enfield, Alastair Magness, Asher Mullokandov, Gavin Kelly, Tanja D. de Gruijl, Miriam Molina-Arcas, Charles Swanton, View ORCID ProfileJulian Downward, Febe van Maldegem
Publicado en: 2024
Editor: Cold Spring Harbor Press
DOI: 10.1101/2024.04.11.588725